Inhibition of Hazara Nairovirus Replication by Small Interfering RNAs and Their Combination with Ribavirin

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2011 May 24

PMID 21600011

Citations 19

Authors

Olivier Flusin

Solenne Vigne

Christophe N Peyrefitte

Michele Bouloy

Jean-Marc Crance

Frederic Iseni

Affiliations

Soon will be listed here.

Abstract

Background: The genus Nairovirus in the family Bunyaviridae contains 34 tick-borne viruses classified into seven serogroups. Hazara virus (HAZV) belongs to the Crimean-Congo hemorrhagic fever (CCHF) serogroup that also includes CCHF virus (CCHFV) a major pathogen for humans. HAZV is an interesting model to study CCHFV due to a close serological and phylogenetical relationship and a classification which allows handling in a BSL2 laboratory. Nairoviruses are characterized by a tripartite negative-sense single stranded RNA genome (named L, M and S segments) that encode the RNA polymerase, the Gn-Gc glycoproteins and the nucleoprotein (NP), respectively. Currently, there are neither vaccines nor effective therapies for the treatment of any bunyavirus infection in humans. In this study we report, for the first time, the use of RNA interference (RNAi) as an approach to inhibit nairovirus replication.

Results: Chemically synthesized siRNAs were designed to target the mRNA produced by the three genomic segments. We first demonstrated that the siRNAs targeting the NP mRNA displayed a stronger antiviral effect than those complementary to the L and M transcripts in A549 cells. We further characterized the two most efficient siRNAs showing, that the induced inhibition is specific and associated with a decrease in NP synthesis during HAZV infection. Furthermore, both siRNAs depicted an antiviral activity when used before and after HAZV infection. We next showed that HAZV was sensitive to ribavirin which is also known to inhibit CCHFV. Finally, we demonstrated the additive or synergistic antiviral effect of siRNAs used in combination with ribavirin.

Conclusions: Our study highlights the interest of using RNAi (alone or in combination with ribavirin) to treat nairovirus infection. This approach has to be considered for the development of future antiviral compounds targeting CCHFV, the most pathogenic nairovirus.

Citing Articles

HuR (ELAVL1) regulates the CCHFV minigenome and HAZV replication by associating with viral genomic RNA.

Ikegawa M, Kano N, Ori D, Fukuta M, Hirano M, Hewson R PLoS Negl Trop Dis. 2024; 18(9):e0012553.

PMID: 39348382 PMC: 11466401. DOI: 10.1371/journal.pntd.0012553.

Hantavirus: an overview and advancements in therapeutic approaches for infection.

Afzal S, Ali L, Batool A, Afzal M, Kanwal N, Hassan M Front Microbiol. 2023; 14:1233433.

PMID: 37901807 PMC: 10601933. DOI: 10.3389/fmicb.2023.1233433.

Antiviral and protective effect of small interfering RNAs against rift valley fever virus in vitro.

Ahmed E, Boseila A, Hanora A, Solyman S Mol Biol Rep. 2023; 50(7):5837-5848.

PMID: 37231214 PMC: 10211306. DOI: 10.1007/s11033-023-08455-9.

Exploring the Potential of Iminosugars as Antivirals for Crimean-Congo Haemorrhagic Fever Virus, Using the Surrogate Hazara Virus: Liquid-Chromatography-Based Mapping of Viral N-Glycosylation and In Vitro Antiviral Assays.

Tyrrell B, Kumar A, Gangadharan B, Alonzi D, Brun J, Hill M Pathogens. 2023; 12(3).

PMID: 36986321 PMC: 10057787. DOI: 10.3390/pathogens12030399.

Cranberry () Extract Impairs Nairovirus Infection by Inhibiting the Attachment to Target Cells.

Mirandola M, Salvati M, Rodigari C, Appelberg K, Mirazimi A, Maffei M Pathogens. 2021; 10(8).

PMID: 34451488 PMC: 8401317. DOI: 10.3390/pathogens10081025.

References

Darwish M, IMAM I, Omar F, HOOGSTRAAL H . Results of a preliminary seroepidemiological survey for Crimean-Congo hemorrhagic fever virus in Egypt. Acta Virol. 1978; 22(1):77. View

Song E, Lee S, Dykxhoorn D, Novina C, Zhang D, Crawford K . Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol. 2003; 77(13):7174-81. PMC: 164789. DOI: 10.1128/jvi.77.13.7174-7181.2003. View

Ge Q, Filip L, Bai A, Nguyen T, Eisen H, Chen J . Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A. 2004; 101(23):8676-81. PMC: 423254. DOI: 10.1073/pnas.0402486101. View

HOOGSTRAAL H . The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa. J Med Entomol. 1979; 15(4):307-417. DOI: 10.1093/jmedent/15.4.307. View

Fire A, Xu S, Montgomery M, Kostas S, Driver S, Mello C . Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998; 391(6669):806-11. DOI: 10.1038/35888. View

Vigne S, Duraffour S, Andrei G, Snoeck R, Garin D, Crance J . Inhibition of vaccinia virus replication by two small interfering RNAs targeting B1R and G7L genes and their synergistic combination with cidofovir. Antimicrob Agents Chemother. 2009; 53(6):2579-88. PMC: 2687203. DOI: 10.1128/AAC.01626-08. View

Maltezou H, Andonova L, Andraghetti R, Bouloy M, Ergonul O, Jongejan F . Crimean-Congo hemorrhagic fever in Europe: current situation calls for preparedness. Euro Surveill. 2010; 15(10):19504. View

Bodur H, Erbay A, Akinci E, Onguru P, Bayazit N, Eren S . Effect of oral ribavirin treatment on the viral load and disease progression in Crimean-Congo hemorrhagic fever. Int J Infect Dis. 2010; 15(1):e44-7. DOI: 10.1016/j.ijid.2010.09.009. View

Sledz C, Holko M, de Veer M, Silverman R, Williams B . Activation of the interferon system by short-interfering RNAs. Nat Cell Biol. 2003; 5(9):834-9. DOI: 10.1038/ncb1038. View

10.

Watanabe T, Umehara T, Kohara M . Therapeutic application of RNA interference for hepatitis C virus. Adv Drug Deliv Rev. 2007; 59(12):1263-76. DOI: 10.1016/j.addr.2007.03.022. View

11.

Whitehouse C . Crimean-Congo hemorrhagic fever. Antiviral Res. 2004; 64(3):145-60. DOI: 10.1016/j.antiviral.2004.08.001. View

12.

Nakata H, Steinberg S, Koh Y, Maeda K, Takaoka Y, Tamamura H . Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs. Antimicrob Agents Chemother. 2008; 52(6):2111-9. PMC: 2415794. DOI: 10.1128/AAC.01299-07. View

13.

Larrat S, Morand P, Bas A, Vigne S, Crance J, Boyer V . Inhibition of Epstein-Barr virus replication by small interfering RNA targeting the Epstein-Barr virus protease gene. Antivir Ther. 2009; 14(5):655-62. View

14.

Jacque J, Triques K, Stevenson M . Modulation of HIV-1 replication by RNA interference. Nature. 2002; 418(6896):435-8. PMC: 9524216. DOI: 10.1038/nature00896. View

15.

Elbashir S, Lendeckel W, Tuschl T . RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001; 15(2):188-200. PMC: 312613. DOI: 10.1101/gad.862301. View

16.

Levin A, Kutznetova L, Kahana R, Rubinstein-Guini M, Stram Y . Highly effective inhibition of Akabane virus replication by siRNA genes. Virus Res. 2006; 120(1-2):121-7. DOI: 10.1016/j.virusres.2006.02.009. View

17.

Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E . Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther. 2003; 8(5):769-76. DOI: 10.1016/s1525-0016(03)00244-2. View

18.

Alkhalil A, Strand S, Mucker E, Huggins J, Jahrling P, Ibrahim S . Inhibition of monkeypox virus replication by RNA interference. Virol J. 2009; 6:188. PMC: 2777875. DOI: 10.1186/1743-422X-6-188. View

19.

Quenelle D, Prichard M, Keith K, Hruby D, Jordan R, Painter G . Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother. 2007; 51(11):4118-24. PMC: 2151443. DOI: 10.1128/AAC.00762-07. View

20.

Smirnova S, SHESTOPALOVA N, REINGOLD V, ZUBRI G, CHUMAKOV M . Experimental Hazara Virus infection in mice. Acta Virol. 1977; 21(2):128-32. View